The Impact of New Driver Mutations on Treatment of NSCLC

Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Lauren Welch, MSN, NP-C, AOCNP, discusses the impact that the discovery of new actionable molecular targets and oncogenic drivers has had on treatment of NSCLC, with at least 6 new targets, all with approved targeted therapies. She suggests that patients have better outcomes with targeted therapies upfront, so that identification of these targets early through broad NGS testing is essential in extending survival in patients with NSCLC.

Related Items

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: